Better Therapeutics, Inc. BTTX
0.00
0.00
NaN
as of 25 Sep
- Market cap
- $850.0K
- P/E
- 0.0×
Follow BTTX
| Sep '23 | Jun '23 | Mar '23 | Dec '22 | Older periods | |
|---|---|---|---|---|---|
| 2,351.81% | (1,021.64%) | (448.56%) | (221.99%) |
+8 more TTM periods Free account |
|
| (162.15%) | (152.41%) | (148.61%) | (107.60%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
575.00% | 585.80% | 778.67% | (783.76%) | |
Free Cash Flow per Share |
(0.71) | (0.93) | (1.28) | (1.28) | |
Free Cash Flow |
(27.40) | (28.91) | (30.45) | (30.11) | |
Capital Expenditures |
(1.32) | (1.76) | (1.66) | (1.18) | |
Piotroski F-Score |
1.00 | 1.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(237.81%) | (282.25%) | (267.20%) | (97.34%) | |
Accounts Payable Turnover |
1.75 | 1.46 | 1.74 | 1.20 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
270.53 | 367.21 | 325.15 | 405.93 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.83 | 0.73 | 0.73 | 0.73 | |
Depreciation/Fixed assets |
30.53 | 25.80 | 21.53 | 22.55 | |
Capex/Depreciation |
(0.42) | (0.59) | (0.59) | (0.43) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.68) | (0.87) | (1.21) | (1.23) | |
Capex per Share |
(0.03) | (0.06) | (0.07) | (0.05) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates